R-warfarin anticoagulant effect.
作者信息
Padrini Roberto, Quintieri Luigi
机构信息
Dipartimento di Medicina - DIMED, Università degli Studi di Padova, via Giustiniani 2, 35128, Padova, Italy.
Dipartimento di Scienze del Farmaco - DSF, Università degli Studi di Padova, via Marzolo 5, 35131, Padova, Italy.
出版信息
Br J Clin Pharmacol. 2017 Oct;83(10):2303-2304. doi: 10.1111/bcp.13300. Epub 2017 May 11.
Abstract
摘要
相似文献
1
R-warfarin anticoagulant effect.R-华法林抗凝作用。
Br J Clin Pharmacol. 2017 Oct;83(10):2303-2304. doi: 10.1111/bcp.13300. Epub 2017 May 11.
2
Response to R-warfarin anticoagulant effect.对华法林抗凝作用的反应。
Br J Clin Pharmacol. 2017 Oct;83(10):2305-2306. doi: 10.1111/bcp.13344. Epub 2017 Jul 23.
3
Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.S-华法林和R-华法林基于理论的药代动力学和药效学及其对国际标准化比值的影响：心脏手术患者的体型、组成和基因型的影响
Br J Clin Pharmacol. 2017 Apr;83(4):823-835. doi: 10.1111/bcp.13157. Epub 2016 Nov 25.
4
The effect of etoricoxib on the pharmacodynamics and pharmacokinetics of warfarin.
J Clin Pharmacol. 2007 May;47(5):620-7. doi: 10.1177/0091270007299758.
5
D-Dimer versus International Normalized Ratio of Prothrombin Time in Ischemic Stroke Patients Treated with Sufficient Warfarin.足量华法林治疗的缺血性中风患者中D-二聚体与凝血酶原时间国际标准化比值的比较
J Stroke Cerebrovasc Dis. 2016 Jul;25(7):1781-1785. doi: 10.1016/j.jstrokecerebrovasdis.2016.03.037. Epub 2016 Apr 18.
6
The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers.
J Clin Pharm Ther. 2008 Feb;33(1):67-73. doi: 10.1111/j.1365-2710.2008.00887.x.
7
Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.通过模拟研究确定，从利伐沙班转换为华法林进行抗凝治疗时，利伐沙班对国际标准化比值的影响。
Br J Clin Pharmacol. 2015 Jun;79(6):959-66. doi: 10.1111/bcp.12571.
8
Enhancement of Warfarin Anticoagulant Reaction in Patients with Repeated Oral Tolvaptan Administration.
Biol Pharm Bull. 2018 Jul 1;41(7):1014-1016. doi: 10.1248/bpb.b17-01008. Epub 2018 May 11.
9
Extreme Elevation of the Prothrombin Time-International Normalized Ratio due to a Probable Interaction between Warfarin and Flutamide.华法林与氟他胺可能相互作用导致凝血酶原时间-国际标准化比值极度升高。
Intern Med. 2019 Nov 15;58(22):3251-3253. doi: 10.2169/internalmedicine.2973-19. Epub 2019 Jul 10.
10
Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.年龄、体重、CYP2C9和VKORC1基因对华法林抗凝反应的影响：中国患者新给药方案的建议
Eur J Clin Pharmacol. 2007 Dec;63(12):1135-41. doi: 10.1007/s00228-007-0381-6. Epub 2007 Sep 27.
引用本文的文献
1
A physiologically-based pharmacokinetic/pharmacodynamic modeling approach for drug-drug-gene interaction evaluation of S-warfarin with fluconazole.基于生理的药代动力学/药效动力学模型在氟康唑与 S-华法林药物-药物-基因相互作用评价中的应用。
CPT Pharmacometrics Syst Pharmacol. 2024 May;13(5):853-869. doi: 10.1002/psp4.13123. Epub 2024 Mar 15.
2
Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.一项基因指导华法林试验的药代动力学和药效学重新评估。
Eur J Clin Pharmacol. 2018 May;74(5):571-582. doi: 10.1007/s00228-018-2422-8. Epub 2018 Feb 2.
3
Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.双氯西林在体内和体外诱导 CYP2C19、CYP2C9 和 CYP3A4。
Br J Clin Pharmacol. 2018 Mar;84(3):510-519. doi: 10.1111/bcp.13467. Epub 2018 Jan 10.
4
Response to R-warfarin anticoagulant effect.对华法林抗凝作用的反应。
Br J Clin Pharmacol. 2017 Oct;83(10):2305-2306. doi: 10.1111/bcp.13344. Epub 2017 Jul 23.
本文引用的文献
1
Theory-based pharmacokinetics and pharmacodynamics of S- and R-warfarin and effects on international normalized ratio: influence of body size, composition and genotype in cardiac surgery patients.S-华法林和R-华法林基于理论的药代动力学和药效学及其对国际标准化比值的影响：心脏手术患者的体型、组成和基因型的影响
Br J Clin Pharmacol. 2017 Apr;83(4):823-835. doi: 10.1111/bcp.13157. Epub 2016 Nov 25.
2
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.《2015/16药理学简明指南：酶》
Br J Pharmacol. 2015 Dec;172(24):6024-109. doi: 10.1111/bph.13354.
3
Warfarin resistance associated with genetic polymorphism of VKORC1: linking clinical response to molecular mechanism using computational modeling.与维生素K环氧化物还原酶复合体1（VKORC1）基因多态性相关的华法林抵抗：利用计算模型将临床反应与分子机制相联系
Pharmacogenet Genomics. 2016 Jan;26(1):44-50. doi: 10.1097/FPC.0000000000000184.
4
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.《2016年IUPHAR/BPS药理学指南：迈向1300个蛋白质靶点与6000种配体之间的精准定量相互作用》
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.
5
The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship to VKORC1 genotype.单次给予（R）-和（S）-华法林单剂量的药代动力学和药效学：与 VKORC1 基因型的关系。
Br J Clin Pharmacol. 2013 Jan;75(1):208-16. doi: 10.1111/j.1365-2125.2012.04335.x.
6
The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors.R-和 S-华法林的群体药代动力学：遗传和临床因素的影响。
Br J Clin Pharmacol. 2012 Jan;73(1):66-76. doi: 10.1111/j.1365-2125.2011.04051.x.
7
A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.一种用于预测年龄、CYP2C9和VKORC1基因型对华法林治疗个体化影响的药代动力学-药效学模型。
Clin Pharmacol Ther. 2007 Apr;81(4):529-38. doi: 10.1038/sj.clpt.6100084. Epub 2007 Feb 14.
8
Human P450 metabolism of warfarin.华法林的人体细胞色素P450代谢
Pharmacol Ther. 1997;73(1):67-74. doi: 10.1016/s0163-7258(96)00140-4.
9
Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model.
Clin Pharmacol Ther. 1994 Sep;56(3):286-94. doi: 10.1038/clpt.1994.139.
10
Human prothrombin metabolism in normal man and in hypocoagulable subjects.正常人和低凝状态受试者的人凝血酶原代谢
J Clin Invest. 1969 Jul;48(7):1292-8. doi: 10.1172/JCI106095.
Zotero 插件